This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Olink Holding Valuation

Is 6XA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6XA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6XA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6XA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6XA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 6XA. This is calculated by dividing 6XA's market cap by their current preferred multiple.
What is 6XA's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$3.25b

6XA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	18.6x
Enterprise Value/EBITDA	-72.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6XA's PS Ratio compare to its peers?

The above table shows the PS ratio for 6XA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.3x
GXI Gerresheimer	1.7x	10.9%	€3.3b
EVT Evotec	1.4x	11.4%	€1.1b
1SXP SCHOTT Pharma KGaA	4.9x	10.7%	€4.6b
SRT3 Sartorius	5.1x	9.2%	€15.4b
6XA Olink Holding	19x	18.6%	€3.3b

Price-To-Sales vs Peers: 6XA is expensive based on its Price-To-Sales Ratio (19x) compared to the peer average (3.5x).

Price to Earnings Ratio vs Industry

How does 6XA's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.9%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 6XA is expensive based on its Price-To-Sales Ratio (19x) compared to the European Life Sciences industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is 6XA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6XA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	19x
Fair PS Ratio	6.9x

Price-To-Sales vs Fair Ratio: 6XA is expensive based on its Price-To-Sales Ratio (19x) compared to the estimated Fair Price-To-Sales Ratio (6.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.